Companies
FrieslandCampina Ingredients
Aequival 2'-FL — Thailand infant/follow-on formula approval.
- Country
- Netherlands
hmo-fermentation
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| food-alt-protein | ✓ | ✓ | ✓ |
Regulatorsfdaefsanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Regulatory approval | Aequival 2'-FL approved by Thai FDA for infant and follow-on formula | dairybusinessmea.com · foodbeverageasia.com · nutraceuticalbusinessreview.com · foodnavigator.com · nutritioninsight.com |
| Revenue | 13.4 billion euros (for Royal FrieslandCampina N.V., 2025) | frieslandcampina.com |
| Headcount | approximately 15,668 (as of March 2026) | frieslandcampina.com |
| Production site | Borculo (Netherlands), Veghel (Netherlands), Bedum (Netherlands), Workum (Netherlands), Delhi (New York) | frieslandcampina.com · frieslandcampinaingredients.com |
| Capacity | Doubled production capacity of whey protein isolate and milk fat globule membrane at Borculo facility (as of 2026) | frieslandcampina.com · frieslandcampinaingredients.com |
Independent sources: dairybusinessmea.com · foodbeverageasia.com · foodnavigator.com · nutraceuticalbusinessreview.com · nutritioninsight.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Human milk oligosaccharides (HMOs) | food-alt-protein | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.